MPRO

biotech | September 26, 2016

Scientists can improve protein-based drugs by reaching into the evolutionary past, a paper published in Nature Biotechnology proposes. As a proof of concept for this approach, the research team from Emory, Children's Healthcare of Atlanta and Georgia Tech showed how "ancestral sequence reconstruction" or ASR can guide engineering of the blood clotting protein known as factor VIII, which is deficient in the inherited disorder hemophilia A....

Pall Corporation | October 04, 2016

Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the launch of breakthrough technologies that for the first time enable integrated, process-scale continuous production of biotherapies in single-use formats. Biopharmaceutical manufacturers are increasingly incorporating continuous technologies to replace traditional batch methods in order to improve consistency, reduce production footprints and shorten lead times. Single-use technologies further...

biotech | February 17, 2017

University of Alabama at Birmingham (UAB) researchers studying rod cell proteins GARP1 and GARP2, or glutamic acid-rich proteins 1 and 2, to learn how they function in normal phototransduction in the eye have found that GARP2 accelerates retinal degeneration in mice that lack another rod cell protein, cyclic guanosine monophosphate (cGMP)-gated cation channel β-subunit, involved in producing the electrical signal....

biotech | March 07, 2017

Despite ominous warnings from the scientific establishment that President Trump is anti-science, there is one area in which he might be more pro-science than President Obama: agriculture. Free from the constraints of hard-line, Obama-era environmentalists who opposed innovations such as genetically engineered crops, the Trump administration can energize the federal government’s sclerotic approach to green-lighting new agricultural biotechnologies. Many groundbreaking products could reduce ...